CompletedInterventionalPhase 1Last updated Jun 7, 2024

Pharmacokinetics and Safety of RV521 Formulations

An Open-label, Single Dose, Three Sequence Study in Healthy Adult Volunteers to Evaluate the Pharmacokinetics, Safety and Tolerability of RV521 Administered as the Drug in Capsule Formulation in the Fed State and the Dry Powder Blend Formulation Dispersed in Water in the Fed and Fasted States

Overview

ClinicalTrials.gov ID: NCT04065698
Lead Sponsor: PfizerINDUSTRY
Brief Summary: The main aims of the study are to assess the pharmacokinetics and safety of single doses of RV521 administered as two different formulations
Study Type: Interventional

Status

Overall Status: Completed
Start Date: Aug 13, 2019Actual
Primary Completion Date: Sep 2, 2019Actual
Completion Date: Sep 9, 2019Actual

Study Record Dates

First Submitted: Aug 20, 2019
First Submitted that Met QC Criteria: Aug 21, 2019
First Posted: Aug 22, 2019Actual
Last Update Submitted that Met QC Criteria: Jun 5, 2024
Last Update Posted: Jun 7, 2024Actual
Last Verified: Jun 2024

NCT05873764Completed

A Study to Learn About Effect of Sisunatovir in Healthy Adult Male Participants

NCT03782662Completed

A Study to Learn About the Drug-drug Interactions of Sisunatovir in Healthy Adult Participants

NCT03258502Completed

A Study to Learn About the Effects of Multiple Doses of Sisunatovir on People With Respiratory Syncytial Virus (RSV) Infection

NCT04225897Terminated

A Study to Learn About the Effects of Sisunatovir in Infants With Respiratory Syncytial Virus Lower Respiratory Tract Infection.

NCT04267822Withdrawn

Study of RV521 in the Treatment of Adult Subjects Who Have Undergone HCT With an URTI With RSV

NCT05712460Completed

A Study to Assess the Safety, Effects and Palatability of Sisunatovir in Healthy Adult Participants